| Literature DB >> 27123439 |
Abstract
Free fatty acids released from human adipose tissue contain a limited amount of non-esterified poly-cis-unsaturated fatty acids. In cases of elevated plasma free fatty acids, this condition ultimately leads to a shift from unsaturated to saturated fatty-acyl chains in membrane phospholipids. Because this shift promotes the physical attractive van der Waals interactions between phospholipid acyl chains, it increases stiffness of both erythrocyte and endothelial membranes, which causes a reduction in both insulin-independent and insulin-dependent Class 1 glucose transporters, a reduction in cell membrane functionality, and a decreased microcirculatory blood flow which results in tissue hypoxia. Against the background of these processes, we review recently published experimental phospholipid data obtained from Drosophila melanogaster and from human erythrocytes of controls and patients with type 2 diabetes, with and without retinopathy, along the way free fatty acids interfere with eye and kidney function in patients with type 2 diabetes and give rise to endoplasmic reticulum stress, reduced insulin sensitivity, and ischemia.Entities:
Keywords: Diabetic nephropathy; Diabetic retinopathy; Free fatty acids; Membrane flexibility; Type 2 diabetes
Year: 2016 PMID: 27123439 PMCID: PMC4847252 DOI: 10.1186/s40200-016-0235-9
Source DB: PubMed Journal: J Diabetes Metab Disord ISSN: 2251-6581
Unsaturation index of non-esterified fatty acids released from human white fat cells, and human serum lipids of healthy subjects
| Fatty acids | Released from white fatt cellsa | Serum lipidsb | ||
|---|---|---|---|---|
| mol% of total fatty acids | total number of double bonds | mol% of total fatty acids | total number of double bonds | |
| C12:0 | 0.61 | - | ||
| C14:0 | 3.51 | - | ||
| C15:0 | 0.40 | - | ||
| C16:0 | 24.97 | - | ||
| C18:0 | 6.14 | - | ||
| C20:0 | 0.08 | - | ||
| C22:0 | 0.02 | - | ||
| ∑ SFA | 27.05 | - | ||
| C14:1 | 0.26 | 0.26 | ||
| C16:1 | 4.40 | 4.40 | ||
| C17:1 | 0.36 | 0.36 | ||
| C18:1 | 40.70 | 40.70 | ||
| C20:1 | 0.58 | 0.58 | ||
| C22:1 | 0.03 | 0.03 | ||
| ∑MUFA | 23.60 | 23.60 | ||
| C18:2 n-6 | 15.74 | 31.49 | 27.47 | 54.94 |
| C20:2 n-9 | 0.02 | 0.03 | ||
| C20:2 n-6 | 0.23 | 0.46 | ||
| C18:3 n-3 | 0.73 | 2.20 | 2.48 | 7.44 |
| C18:3 n-6 | 0.05 | 0.15 | ||
| C20:3 n-6 | 0.21 | 0.64 | ||
| C20:3 n-3 | 0.03 | 0.08 | ||
| C20:4 n-6 | 0.51 | 2.04 | 4.48 | 17.92 |
| C20:4 n-3 | 0.04 | 0.14 | ||
| C22:4 n-6 | 0.08 | 0.33 | ||
| C20:5 n-3 | 0.09 | 0.45 | 1.56 | 7.80 |
| C22:5 n-6 | 0.01 | 0.04 | ||
| C22:5 n-3 | 0.09 | 0.45 | ||
| C22:6 n-3 | 0.12 | 0.70 | 13.36 | 80.16 |
| Total | 100.00 | 100.00 | ||
| UI | 85.53 | 191.86 | ||
For conversion to mol%, athe data listed by Raclot et al. [36] were multiplied by: (MWFFA)-1 · 103 · 0. 272, and bthose by Wang et al. [37] by 0. 142. The unsaturation index was calculated as the mean number of cis double bonds per fatty-acid residue multiplied by 100. SFA saturated fatty acid, MUFA monounsaturated fatty acid, MW, molecular weight
Erythrocyte fatty acid composition of controls, individuals with type 2 diabetes without diabetic retinopathy, and individuals with type 2 diabetes with diabetic retinopathya
| Fatty acid category | Controls | Individuals with type 2 diabetes without retinopathy | Individuals with type 2 diabetes with retinopathy |
|---|---|---|---|
| SFAs (%) | 41.83 | 43.99 | 46.61 |
| MUFAs (%) | 18.85 | 21.68 | 21.26 |
| PUFAs (%) | 37.97 | 31.92 | 29.47 |
SFA saturated fatty acid, MUFA monounsaturated fatty acid, PUFA poly-cis-unsaturated fatty acid
aOriginal data listed by Koehrer et al. [39]
Fig. 1Proposed steps in the development of type 2 diabetes model. Although the results of genome-wide screen for type 2 diabetes susceptibility genes is still being debated, we hypothesize that the involved genes of the disease lead to an increase in plasma free fatty acids; FFA: free fatty acid; GLUT: glucose transporter
Values of glucose effectiveness (SG) and insulin sensitivity (SI) for minimal model
| Units SG | Control subjects | Type 2 diabetes |
| Compart-ment | Tracher | Ref. |
|---|---|---|---|---|---|---|
| min-1 | 0.016 ± 0.001 | 0.010 ± 0.001 | <0.01 | one | no | 48 |
| 0.023 ± 0.012 | 0.013 ± 0.001 | <0.05 | one | no | 49 | |
| 0.023 ± 0.012 | 0.016 ± 0.009 | <0.001 | one | no | 50a | |
| h-1 | 1.2 ± 0.16 | 0.81 ± 0.11 | <0.001 | one | no | 51 |
| 0.41 ± 0.04 | 0.33 ± 0.02 | <0.001 | two | 13C | 51 | |
| 0.52 ± 0.05 | 0.37 ± 0.02 | <0.001 | two | 2H | 51 | |
| Units SI | ||||||
| 10-4∙min-1∙(mU/L)-1 | 11.8 ± 2.6 | 6.7 ± 0.8 | <0.01 | one | no | 49 |
| 13.45 ± 11.12 | 5.31 ± 3.98 | <0.01 | one | no | 50 a | |
| pmol∙L-1∙h-1 | 0.0062 ± 0.0006 | 0.0019 ± 0.0006 | <0.01 | one | no | 51 |
| 0.0082 ± 0.0012 | 0.0036 ± 0.0006 | <0.001 | two | 13C | 51 | |
| 0.0098 ± 0.0013 | 0.0042 ± 0.0008 | <0.001 | two | 2H | 51 |
aMore than 10 years before the development of type 2 diabetes